3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
58
Small Cell Lung Carcinoma
22
Carcinoma, Hepatocellular
17
Neoplasms
15
Lung Neoplasms
14
Biliary Tract Neoplasms
12
Neoplasm Metastasis
11
Breast Neoplasms
11
Recurrence
10
Squamous Cell Carcinoma of Head and Neck
9
Melanoma
9
Carcinoma
9
Advanced Solid Tumors
8
Triple Negative Breast Neoplasms
7
Stomach Neoplasms
7
Lymphoma, Large B-Cell, Diffuse
7
Liver Neoplasms
7
Head and Neck Neoplasms
7
Urinary Bladder Neoplasms
6
Ovarian Neoplasms
6
Carcinoma, Renal Cell
6
Prostatic Neoplasms
5
Lymphoma
5
Uterine Cervical Neoplasms
4
Neoplasms by Site
4
Multiple Myeloma
4
Lymphoma, Follicular
4
Colorectal Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Neoplasms
3
Interventions
tremelimumab
1
durvalumab
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Non Small Cell Lung Cancer NSCLC
×
durvalumab
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA